latanoprostene bunod ophthalmic (Rx)

Brand and Other Names:Vyzulta
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms and Strengths

ophthalmic solution

  • 0.024%

Elevated Intraocular Pressure

Indicated for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Instill 1 drop in affected eye(s) qDay in the evening

Dosing Considerations

Do not administer latanoprostene bunod ophthalmic solution more often than qDay since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect

If latanoprostene bunod ophthalmic solution is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least 5 minutes apart

Dosage Forms and Strengths

ophthalmic solution

  • 0.024%

Elevated Intraocular Pressure

Indicated for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

≤16 years: Not recommended due to potential safety concerns related to increased pigmentation following long-term chronic use

>16 years: Instill 1 drop in affected eye(s) qDay in the evening

Next:

Adverse Effects

1-10%

Hyperemia (6%)

Eye irritation (4%)

Eye pain (3%)

Instillation site pain (2%)

Previous
Next:

Warnings

Contraindications

None

Cautions

Increased pigmentation to tissues may occur; most frequently reported changes with prostaglandin analogs have been of the iris and periorbital tissue (eyelid) and is expected to increase for the duration of treatment; regularly examine patients who develop noticeably increased iris pigmentation

Gradual increases in length, thickness, and number of lashes have been reported

Caution with a history of intraocular inflammation (iritis/uveitis); avoid if active intraocular inflammation exists, as it may exacerbate this condition

Macular edema, including cystoid macular edema, reported; caution in patients with aphakia pseudophakia with a torn posterior lens capsule, or with known risk factors for macular edema

Bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products has been reported; containers may be inadvertently contaminated by patients who typically had a concurrent corneal disease or an ocular epithelial surface disruption

Remove contact lenses before administration because product contains benzalkonium chloride; lenses may be reinserted 15 minutes after administration

Previous
Next:

Pregnancy

Pregnancy

There are no available human data for the use during pregnancy to inform any drug associated risks

Latanoprostene bunod has caused miscarriages, abortion, and fetal harm in rabbits; when administered IV to pregnant rabbits at exposures ≥0.28 times the clinical dose was shown to be abortifacient and teratogenic

Doses ≥20 mcg/kg/day (23 times the clinical dose) produced 100% embryofetal lethality; structural abnormalities (eg, anomalies of the great vessels and aortic arch vessels, domed head, sternebral and vertebral skeletal anomalies, limb hyperextension and malrotation, abdominal distension and edema) were observed in rabbit fetuses

Latanoprostene bunod was not teratogenic rats when administered IV at 150 mcg/kg/day (87 times the clinical dose)

Lactation

There are no data on the presence of latanoprostene bunod in human milk, the effects on the breastfed infant, or the effects on milk production

Developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for latanoprostene bunod, and any potential adverse effects on the breastfed infant from latanoprostene bunod

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Believed to lower intraocular pressure by increasing outflow of aqueous humor through the trabecular meshwork and uveoscleral routes

Intraocular pressure is a major risk factor for glaucoma progression; reduction of intraocular pressure reduces risk of glaucomatous visual field loss

Absorption

Peak plasma time, post Day 1 and Day 28 administration: 5 minutes

Peak plasma concentration, latanoprost acid [LLOQ] 30 pg/mL: 59.1 pg/mL (Day 1); 51.1 pg/mL (Day 28)

Metabolism

After topical ocular administration, latanoprostene bunod is rapidly metabolized in the eye to latanoprost acid (active moiety), an F2-alpha prostaglandin analog, and butanediol mononitrate

After latanoprost acid reaches the systemic circulation, it is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid beta-oxidation Butanediol mononitrate is metabolized to 1,4-butanediol and nitric oxide

The metabolite 1,4-butanediol is further oxidized to succinic acid and enters the tricarboxylic acid (TCA) cycle

Excretion

Elimination of latanoprost acid from human plasma is rapid as latanoprost acid plasma concentration dropped below the LLOQ (30 pg/mL) in the majority of subjects by 15 min following ocular administration of latanoprostene bunod 0.024% in human

Previous
Next:

Administration

Ophthalmic Administration

For ophthalmic use only

Remove contact lenses before administering ophthalmic solution (if applicable)

If ≥1 topical ophthalmic drug is being used, wait least 5 minutes between applications

Instruct patients to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections

Storage

Unopened bottle: Store in refrigerator at 2-8ºC (36-46ºF)

Opened bottles: Store at 2-25ºC (36-77ºF) for up to 8 weeks

During shipment, bottles may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 14 days

Protect from light

Do not freeze

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.